Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study

Iwasaki,Hiroyuki; Yamazaki,Haruhiko; Takasaki,Hirotaka; Suganuma,Nobuyasu; Nakayama,Hirotaka; Toda,Soji; Masudo,Katsuhiko

doi:10.3892/ol.2018.9553

Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study

Authors:
- Hiroyuki Iwasaki
- Haruhiko Yamazaki
- Hirotaka Takasaki
- Nobuyasu Suganuma
- Hirotaka Nakayama
- Soji Toda
- Katsuhiko Masudo
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa 241‑8515, Japan, Department of Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa 241‑8515, Japan, Department of Surgical Treatment, Yokohama City University Hospital, Yokohama, Kanagawa 236‑0004, Japan, Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa 232‑0024, Japan
Published online on: October 5, 2018 https://doi.org/10.3892/ol.2018.9553
Pages: 7271-7277

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid cancer (ATC) is associated with an extremely poor prognosis and is resistant to the majority of chemotherapies. In 2015, lenvatinib was approved for treating ATC in Japan. The present study aimed to evaluate the overall survival (OS) of patients with ATC treated with lenvatinib. A total of 23 patients with a definitive histological diagnosis of ATC who were treated at Kanagawa Cancer Center (Yokohama, Kanagawa. Japan) were enrolled. Surgical treatment was possible in 10 patients (including one debulking surgery), and lenvatinib treatment was postoperatively started. The remaining 13 patients were not eligible for debulking surgery; thus, lenvatinib was promptly approved as a life‑saving treatment. The therapeutic effect was determined according to the Response Evaluation Criteria In Solid Tumors criteria (ver.1.1). The patients exhibited a lenvatinib response rate of 17.4% and a disease control rate of 43.5%. However, lenvatinib was associated with a 100% incidence of treatment‑related adverse events (AEs), with hypertension being the most common AE (91.3%). Additionally, dose interruptions and reductions were required due to the development of tumor fistulas or other tumor‑related AEs, and 9 (39.1%) patients discontinued treatment due to grade 3 or higher AEs. The median OS time was 166 days. Overall, the present study demonstrated the effectiveness of lenvatinib against ATC, which is often chemotherapy‑resistant. Successful treatment of fistulas developing due to tumor necrosis at the site of the primary lesion is crucial for improving the patient outcome. The response to lenvatinib in patients with ATC varies on a case‑by‑case basis and requires further investigation in future studies.

View Figures

View References

1	Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR and Anderson WF: Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev. 18:1092–1100. 2009. View Article : Google Scholar : PubMed/NCBI
2	Lowe NM, Loughran S, Slevin NJ and Yap BK: Anaplastic thyroid cancer: The addition of systemic chemotherapy to radiotherapy led to an observed improvement in survival-a single centre experience and review of the literature. In: ScientificWorldJournal. 2014:6745832014.
3	Kebebew E, Greenspan FS, Clark OH, Woeber KA and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 103:1330–1335. 2005. View Article : Google Scholar : PubMed/NCBI
4	Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H and Samaan NA: Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 66:321–330. 1990. View Article : Google Scholar : PubMed/NCBI
5	Smallridge RC and Copland JA: Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 22:486–497. 2010. View Article : Google Scholar : PubMed/NCBI
6	Neff RL, Farrar WB, Kloos RT and Burman KD: Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 37:525–538. 2008. View Article : Google Scholar : PubMed/NCBI
7	Oh EM, Lee KE, Kwon H, Kim EY, Bae DS and Youn YK: Analysis of patients with anaplastic thyroid cancer expected to have curative surgery. J Korean Surg Soc. 83:123–129. 2012. View Article : Google Scholar : PubMed/NCBI
8	Bisof V, Rakusic Z and Despot M: Treatment of patients with anaplastic thyroid cancer during the last 20 years: Whether any progress has been made? Eur Arch Otorhinolaryngol. 272:1553–1567. 2015. View Article : Google Scholar : PubMed/NCBI
9	Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, et al: Lenvatinib for anaplastic thyroid cancer. Front Oncol. 7:252017. View Article : Google Scholar : PubMed/NCBI
10	Matsui J and Funahashi Y: Preclinical biomarker research and patient stratification of molecular target agents: The anti-angiogenic inhibitor Lenvatinib mesylate (E7080) (Japanese). Nihon Yakurigaku Zasshi. 142:162–166. 2013. View Article : Google Scholar : PubMed/NCBI
11	Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014:6387472014. View Article : Google Scholar : PubMed/NCBI
12	Yamazaki H, Shimizu S, Iwasaki H, Yoshida T, Suganuma N, Yamanaka T, Kojima I, Masudo K, Toda S, Nakayama H and Masuda M: Efficacy and safety of lenvatinib for unresectable anaplastic thyroid cancer. Gan To Kagaku Ryoho. 44:695–697. 2017.PubMed/NCBI
13	Tuttle RM, Haugen B and Perrier ND: Updated american joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth edition): What changed and why? Thyroid. 27:751–756. 2017. View Article : Google Scholar : PubMed/NCBI
14	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
15	Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines (Japanese). Int J Clin Oncol. 9 (Suppl):1–82. 2004.
16	Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP and de la Fouchardière C: Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 11:4692011. View Article : Google Scholar : PubMed/NCBI
17	Ain KB, Egorin MJ and DeSimone PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group. Thyroid. 10:587–594. 2000. View Article : Google Scholar : PubMed/NCBI
18	Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, et al: Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 24:232–240. 2014. View Article : Google Scholar : PubMed/NCBI
19	Goffredo P, Thomas SM, Adam MA, Sosa JA and Roman SA: Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: An analysis of 335 cases. Ann Surg Oncol. 22:4166–4174. 2015. View Article : Google Scholar : PubMed/NCBI
20	Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, et al: American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 22:1104–1139. 2012. View Article : Google Scholar : PubMed/NCBI
21	Perrier ND, Brierley JD and Tuttle RM: Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 68:55–63. 2018. View Article : Google Scholar : PubMed/NCBI
22	Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY and Clark OH: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 91:2335–2342. 2001. View Article : Google Scholar : PubMed/NCBI
23	Haymart MR, Banerjee M, Yin H, Worden F and Griggs JJ: Marginal treatment benefit in anaplastic thyroid cancer. Cancer. 119:3133–3139. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hui EP, Ma BB, King AD, Mo F, Chan SL, Kam MK, Loong HH, Ahuja AT, Zee BC and Chan AT: Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol. 22:1280–1287. 2011. View Article : Google Scholar : PubMed/NCBI
25	Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, et al: Phase II study of sunitinib in recurrent ormetastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 28:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
26	Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A and Remick SC: Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 23:600–604. 2013. View Article : Google Scholar : PubMed/NCBI
27	Weitzman SP and Cabanillas ME: The treatment landscape in thyroid cancer: A focus on cabozantinib. Cancer Manag Res. 7:265–278. 2015.PubMed/NCBI
28	Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, et al: Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 36:7–13. 2018. View Article : Google Scholar : PubMed/NCBI
29	Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B and Cabanillas ME: Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 24:918–922. 2014. View Article : Google Scholar : PubMed/NCBI
30	Mani N, McNamara K, Lowe N, Loughran S and Yap BK: Management of the compromised airway and role of tracheotomy in anaplastic thyroid carcinoma. Head Neck. 38:85–88. 2016. View Article : Google Scholar : PubMed/NCBI